Pershing Square Announces New Position in Valeant Pharmaceuticals International

AMSTERDAM--(BUSINESS WIRE)-- Regulatory News:

Pershing Square Holdings, Ltd. (ticker: PSH:NA) announced today a new position in Valeant Pharmaceuticals International, Inc. (ticker: NYSE: VRX) representing approximately 16.9% of the PSH portfolio (based on the closing NAV of PSH and the closing share price of VRX on Friday, 6 March 2015).

Pershing Square Capital Management, L.P., the investment manager for Pershing Square Holdings, Ltd., announced that various funds it manages have purchased 16,473,933 shares of Valeant Pharmaceuticals International, Inc., representing 4.9% of Valeant.

About Pershing Square Holdings, Ltd.

Pershing Square Holdings, Ltd. is a concentrated, research‐intensive, fundamental value investor in the public markets.

MEDIA CONTACTS
StockWell Communications
Tim Burt, +44 (0)20 7240 2486
[email protected]

Source: Pershing Square Holdings, Ltd.

You May Also Be Interested In

• AV’s LOCUST® Selected for Nearly $500 million Army Counter-UAS Contract for Enduring-High Energy Laser (E-HEL) Program
• Marquis Who's Who Recognizes Balázs Nagy for Leadership in AI Workforce Development
• CZR Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Caesars Entertainment to Fertitta Entertainment